Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infections

November 28, 2012

Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the company, ONMEL is the only FDA-approved oral treatment dosed in a once-a-day 200mg single tablet of itraconazole. ONMEL uses Meltrex (melt extrusion) Technology.

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free